Title	Date	Price
Marketing Drugs in an Era of Pharmacovigilance - Best practice after drug safety scares and the implications for the future Introduction There have been several drug safety scares over the last five years, most notably the withdrawal of Vioxx and the problems with the SSRI antidepressants. With growing public and physician...	Dec, 2005	€9 690
Opioid Abuse - Hooked on Generics? Introduction Opioid abuse is a growing medical challenge, yet few developments have been made in its treatment in recent years. The market requires clarification of the goals of therapy - to remove the...	Dec, 2005	€3 230
Juvenile Arthritis - A Niche In The Market Introduction Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). Pediatric rheumatology is a growing specialty that...	Dec, 2005	€3 230
Therapeutic Vaccines: More Trials and Tribulations Introduction Therapeutic vaccines have faced numerous setbacks in recent years. The only three vaccines to reach the market have had insignificant sales, while the pipeline has seen numerous high-profile...	Dec, 2005	€6 460
Inhalable Drug Delivery: Industry Holds its Breath in Anticipation of Systemic Success Introduction Currently driven by the needs of the expanding respiratory market, the inhalable drug delivery sector has also been invigorated by the promise of growth through the systemic delivery of drugs...	Dec, 2005	€6 460
Biogen-IDEC: PharmaVitae Profile 2005 Introduction This company analysis examines the current position and future outlook for Biogen-IDEC in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and...	Dec, 2005	€4 845
Stakeholder Insight: COPD - Another Reason to Quit Introduction COPD is a deadly disease of the elderly, with patients suffering years of progressive discomfort and disability with no pharmacological interventions able to slow the progressive decline in...	Dec, 2005	€10 000
OTC Healthcare in Ireland to 2010 Introduction This databook is a detailed information resource covering all the key data points on OTC Healthcare in Ireland. It includes comprehensive value volume segmentation and market share data....	Feb, 2007	€396
Bayer: PharmaVitae Profile 2005 Introduction This company analysis examines the current position and future outlook for Bayer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline...	Dec, 2005	€4 845
Takeda: PharmaVitae Profile 2005 Introduction This analysis examines the current position and future outlook for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis...	Dec, 2005	€4 845
Shionogi: PharmaVitae Profile 2005 Introduction This company analysis examines the current position and future outlook for Shionogi in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline...	Dec, 2005	€4 845
Solvay: PharmaVitae Profile 2005 Introduction This analysis examines the current position and future outlook for Solvay in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis...	Dec, 2005	€4 845
Eisai: PharmaVitae Profile 2005 Introduction This company analysis examines the current position and future outlook for Eisai in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline...	Dec, 2005	€4 845
Eli Lilly: PharmaVitae Profile 2005 Introduction This company analysis examines the current position and future outlook for Eli Lilly in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline...	Dec, 2005	€4 845
Sweden Pharmaceuticals 2005 Snapdata's Sweden Pharmaceuticals 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts. The report gives an instant overview of the Swedish pharmaceutical market,...	Dec, 2005	€240
Italy Pharmaceuticals 2005 Snapdata's Italy Pharmaceuticals 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts. The report gives an instant overview of the Italian pharmaceutical market,...	Dec, 2005	€240
Pharmacovigilance: A New Era of Drug Safety Introduction A series of high profile safety concerns, such as the withdrawal of Vioxx (rofecoxib) and the link between antidepressants and suicidal thoughts in children over the last two years has made...	Dec, 2005	€6 460
Poland OTC Pharmaceuticals 2005 Snapdata's Poland OTC Pharmaceuticals 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts. The report gives an instant overview of the Polish OTC pharmaceutical...	Dec, 2005	€240
OTC Healthcare in Italy to 2010 Introduction This databook is a detailed information resource covering all the key data points on OTC Healthcare in Italy. It includes comprehensive value volume segmentation and market share data. The...	Feb, 2007	€396
Stakeholder Insight: Hypertension - Multiple Layers of Therapy Cover all Eventualities Introduction Hypertension is a deadly disease and an important global public health challenge. Datamonitor estimates that there are currently 192m people with hypertension in the seven major markets, and...	Dec, 2005	€10 000